MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.29 -1.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.29

Max

1.32

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	49
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+105.38% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-624K 80M
Eelmine avamishind	2.82
Eelmine sulgemishind	1.29

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First Quarter Net Rose On Strong Demand

15. apr 2026, 17:13 UTC

Suurimad hinnamuutused turgudel

Tesla Shares Rise on Completion of AI5 Chip Design Process

15. apr 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15. apr 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15. apr 2026, 22:41 UTC

Tulu

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15. apr 2026, 22:38 UTC

Tulu

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15. apr 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. apr 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15. apr 2026, 22:14 UTC

Tulu

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15. apr 2026, 22:12 UTC

Tulu

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology Swings to Loss in 1Q>300433.SZ

15. apr 2026, 22:07 UTC

Tulu

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15. apr 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15. apr 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15. apr 2026, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. apr 2026, 20:30 UTC

Tulu

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. apr 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15. apr 2026, 19:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15. apr 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15. apr 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15. apr 2026, 18:58 UTC

Market Talk

Uudisväärsed sündmused

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15. apr 2026, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15. apr 2026, 17:45 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15. apr 2026, 16:58 UTC

Tulu

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15. apr 2026, 16:52 UTC

Tulu

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15. apr 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15. apr 2026, 16:37 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

105.38% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 105.38%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.